Dr. Angelika Vlachou

Partner

Dr. Angelika Vlachou has been investing venture capital in biotech, pharma and life science start-ups for over 10 years. Over the course of her career, she has managed many transactions ranging from seed-stage venture capital and growth financing to licensing agreements, trade sale transactions and IPOs. Her expertise is also based on her virology-molecular biology research experience. One of her strengths is to combine scientific innovation with commercial potential. She is a valued sparring partner for founders, investors and stakeholders. With a doctorate in biology, she started her professional career in investment banking.

Portfolio

Posts & mentions

Press
13. December 2024

Lindis Blood Care Announces Successful Financing for its Tumor-Cell-Removal Medical Device, CATUVAB®

First closing of funding round supported by Brandenburg Kapital, High-Tech Gründerfonds, existing and new private investors; second closing expected by the end of Q1 2025 Funds to be used in preparing for upcoming approval and product launch of CATUVAB® in Europe CATUVAB® is a novel approach designed to be a safe and cost-effective way to reliably remove tumor cells from autologous blood Hennigsdorf, Germany – 12 December, 2024: Lindis Blood Care, a company aiming
 
Press
14. November 2024


SRTD biotech secures seed financing: Side-effect free
RNA therapeutics active only in diseased cells

Jülich, Germany, 14 November 2024 – Jülich-based biotech start-up SRTD biotech GmbH has successfully closed a seven-figure seed financing round. The company will use the fresh capital to accelerate the development of novel RNA therapeutics. Based on a proprietary platform technology, SRTD biotech aims to develop highly efficient RNA-based drugs that are active only in diseased cells. The round was led by High-Tech Gründerfonds (HTGF), alongside renowned business angels who have back
 
Press
13. November 2024

mediaire transforms radiology with AI, securing a European €12 million investment to fuel global growth

Berlin, Paris, 13 November 2024 – While Generative AI is creating a buzz across industries and remains in the early stages of the hype cycle, AI in radiology is no longer just a vision for the future. mediaire’s proven AI value is already happening in over 350 hospitals and clinics across Europe, where the German radiology innovator’s AI portfolio is transforming how radiologists work. With this success, mediaire has secured a €12 million European-led financing round, headed by lead
 
Blog
18. January 2024

2024: Trends, opportunities and challenges for founders

What trends and technologies can we expect to see in 2024? And what are the opportunities and challenges that founders will face? Our Partners Dr. Angelika Vlachou, Dr. Markus Kückelhaus and Markus Kreßmann provide an outlook, focusing on our investment fields industrial tech, life sciences & chemistry, and digital tech. Industrial Tech, Deep Tech and Climate Tech: An outlook by Dr. Markus Kückelhaus In the traditional industrial tech cluster, which encompasses fields such a
 
Press
15. September 2023

Successful exit for HTGF: adivo joins Zoetis to bring the benefits of species-specific antibody therapies to pet owners worldwide

adivo’s team and platform will strengthen Zoetis’ capabilities in therapeutic antibody drug discovery for companion animals. High-Tech Gründerfonds (HTGF) was among the first investors in a seed round in 2018 together with OCCIDENT and MorphoSys AG and closely supported the successful development of adivo. Dr. Kathrin Ladetzki-Baehs, Founder and CEO of adivo: “I look forward to seeing what our team can achieve as part of a leading organization with global reach while continuing
 
Press
23. May 2023

smartbax Announces Seed Financing of €1.2 Million to Develop Next-generation Antibiotics

Munich, Germany, May 23, 2023 – smartbax, a biotech company developing next-generation antibiotics against multi-drug resistant bacteria, today announced the close of its seed financing round of €1.2 million from Boehringer Ingelheim Venture Fund (BIVF) and High-Tech Gründerfonds (HTGF), bringing smartbax’s total capital raised to €1.9 million. The funds will be used to advance smartbax’s small molecule antibiotics through preclinical studies, expand the company’s scientific tea